This is a preview of subscription content, log in via an institution to check access.
References
Data on file. Novartis Satellite Symposium from the Third International Conference on New Trends in Clinical and Experimental Immunosuppression: 1998 Feb 12–15; Geneva
Appel Dingemanse S, Wong R, Dou et al. First pharmacokinetic study with SDZ RAD in stable lung transplant recipients. Transplantation 1998 Jun 27; 65: S188
Doyle R, Wong R, Newmark R, et al. Safety and tolerability of two different single doses of SDZ RAD in lung transplant recipients. Transplantation 1998 Jun; 65: S158
Schuurman H-J, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997 Jul 15; 64: 32–5
Hausen B, Boeke K, Berry GJ, et al. SDZ RAD, a new rapamycin analogue, effectively suppresses rat lung allograft rejection. 3rd International Conference on New Trends in Clinical and Experimental Immunosuppression: 1998 Feb 12; 153
Hausen B, Christians U, Ikonen T, et al. Concurrent drug trough level monitoring improves design and outcome of primate lung transplant study using the novel rapamycin derivative SDZ RAD and microemulsion cyclosporine. 3rd International Conference on New Trends in Clinical and Experimental Immunosuppression: 1998 Feb 12; 86
Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997 Jul 15; 64: 36–42
Rights and permissions
About this article
Cite this article
SDZ RAD. Drugs R&D 1, 97–99 (1999). https://doi.org/10.2165/00126839-199901010-00032
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199901010-00032